Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 20

Sort by

Sort Order Select

Journal Articles

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Natalie F. Uy, MD, Edward Pequignot, Noelle V. Frey, MD, Megan Davis, PhD, Elizabeth O. Hexner, MD, Stephen J. Schuster, MD, Saar Gill, MD PhD, Alison W. Loren, MD, Stephan A Grupp, MD PhD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Joan Gilmore, BS, Lester Lledo, RN,NP, Wei-Ting Hwang, PhD, Don L. Siegel, MD PhD, Bruce L Levine, PhD, Carl H June, MD, David L. Porter, MD

Blood (2020) 136 (Supplement 1): 30–32.

https://doi.org/10.1182/blood-2020-141224

Published: 2020

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Elise A. Chong, MD, James N. Gerson, MD, Daniel J. Landsburg, MD, Sunita Dwivedy Nasta, MD, Jakub Svoboda, MD, David L. Porter, MD, Karen Dengel, BSN, RN, Don L. Siegel, MD PhD, Joan Gilmore, BS, Stefan K. Barta, MD MRCP, MS, Bruce L Levine, PhD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2019) 134 (Supplement_1): 594.

https://doi.org/10.1182/blood-2019-131078

Published: 2019

Journal Articles

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Blood (2019) 134 (Supplement_1): 1863.

https://doi.org/10.1182/blood-2019-131515

Published: 2019

Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 1909.

https://doi.org/10.1182/blood-2019-122396

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

J. Joseph Melenhorst, PhD, David L. Porter, MD, Lifeng Tian, PhD, Simon F Lacey, PhD BS, Christopher L Nobles, PhD, Joseph A Fraietta, PhD, Noelle V. Frey, MD, Irina Kulikovskaya, Minnal Gupta, Regina M Young, PhD, David E Ambrose, BS, Don L. Siegel, MD PhD, Frederic D Bushman, PhD, Carl H June, MD

Blood (2018) 132 (Supplement 1): 699.

https://doi.org/10.1182/blood-2018-99-117390

Published: 2018

Journal Articles

Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL)

Christopher L Nobles, PhD, John K Everett, Shantan Reddy, Joseph A Fraietta, PhD, David L. Porter, MD, Noelle V. Frey, MD, Stephan A. Grupp, MD PhD, Don L. Siegel, MD PhD, Simon F Lacey, PhD BS, Carl H June, MD, Frederic D Bushman, PhD, J. Joseph Melenhorst, PhD

Blood (2018) 132 (Supplement 1): 4548.

https://doi.org/10.1182/blood-2018-99-117034

Published: 2018

Journal Articles

CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia

Elise A. Chong, MD, Bruce L Levine, PhD, Stephan A. Grupp, MD PhD, Megan Davis, PhD, Don L. Siegel, MD PhD, Shannon L. Maude, MD PhD, Whitney Lynn Gladney, PhD, Noelle V. Frey, MD, David L. Porter, MD, Carl H June, MD, Stephen J. Schuster, MD

Blood (2018) 132 (Supplement 1): 197.

https://doi.org/10.1182/blood-2018-197

Published: 2018

Journal Articles

Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate

Blood (2018) 132 (Supplement 1): 298.

https://doi.org/10.1182/blood-2018-99-115418

Published: 2018

Journal Articles

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

Ehren Dancy, MD, Alfred L. Garfall, MD, Adam D. Cohen, MD, Joseph A Fraietta, PhD, Megan Davis, PhD, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Edward A. Stadtmauer, MD FACP, Dan T. Vogl, MD, Adam Waxman, MD, Aaron P. Rapoport, MD, Michael C. Milone, MD PhD, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2018) 132 (Supplement 1): 1886.

https://doi.org/10.1182/blood-2018-99-115319

Published: 2018

Journal Articles

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

Blood (2017) 130 (Supplement 1): 3181.

https://doi.org/10.1182/blood.V130.Suppl_1.3181.3181

Published: 2017

Journal Articles

Erythrocyte Rigidity Affects Blood Clot Contraction and Formation of Polyhedrocytes

Valerie Tutwiler, Rustem I. Litvinov, PhD, Chandrasekaran Nagaswami, J. Eric Russell, MD, Don L. Siegel, MD, PhD,, Carlos Hipolito Villa, MD PhD, Daniel Pan, PhD, Vladimir R Muzykantov, MD PhD, John W. Weisel

Blood (2016) 128 (22): 3814.

https://doi.org/10.1182/blood.V128.22.3814.3814

Published: 2016

Journal Articles

Coupling Therapeutics to Human Erythrocytes Demonstrates Target-Dependent Effects on Red Cell Physiology While Preserving Efficacy

Carlos Hipolito Villa, MD PhD, Daniel Pan, PhD, Ian Johnston, BS, Colin F Greineder, MD PhD, Marion E. Reid, PhD, Douglas B. Cines, MD, Mortimer Poncz, MD, Don L. Siegel, MD, PhD,, Vladimir R Muzykantov, MD PhD

Blood (2016) 128 (22): 701.

https://doi.org/10.1182/blood.V128.22.701.701

Published: 2016

Journal Articles

Thrombomodulin Fusion Proteins Coupled to Human Erythrocytes Demonstrate Anti-Thrombotic and Anti-Inflammatory Activity

Carlos Hipolito Villa, MD PhD, Colin F Greineder, MDPhD, Ian Johnston, BS, Daniel Pan, PhD, Ronald Carnemolla, PhD, Douglas B. Cines, MD, Mortimer Poncz, MD, Don L. Siegel, MD, PhD,, Vladimir R Muzykantov, MDPhD

Blood (2015) 126 (23): 3493.

https://doi.org/10.1182/blood.V126.23.3493.3493

Published: 2015

Journal Articles

Inhibition of ADAMTS13 Activity By Human Neutrophil Peptide 1 (HNP-1): Potential Link Between Inflammation, Onset of Thrombotic Thrombocytopenic Purpura, and Other Thrombosis

Jialing Bao, PhD, Khalil Bdeir, PhD, Don L. Siegel, MD, PhD, Douglas B. Cines, MD, X. Long Zheng, MD, PhD

Blood (2014) 124 (21): 599.

https://doi.org/10.1182/blood.V124.21.599.599

Published: 2014

Journal Articles

Autoantibody Epitope Mapping By Hydrogen-Deuterium Exchange Mass Spectrometry at Nearly Single Amino Acid Residue Resolution Reveals Novel Exosites on ADAMTS13 Critical for Substrate Recognition and Mechanism of Autoimmune Thrombotic Thrombocytopenic Purpura

Veronica C. Casina, PhD, Wenbing Hu, PhD, Hayley A. Hanby, B.S., Brandy Pickens, PhD, Leland Mayne, PhD, Eric Ostertag, MD, PhD, Stephen Kacir, PhD, Don L. Siegel, MD, PhD, S. Walter Englander, PhD, X. Long Zheng, MD, PhD

Blood (2014) 124 (21): 108.

https://doi.org/10.1182/blood.V124.21.108.108

Published: 2014

Journal Articles

Erythrocyte Advanced Glycation End-Products as Novel Mediators of Endothelial Dysfunction Following Transfusion

Nilam S. Mangalmurti, MD, Jessica Friedman, BS, Don L. Siegel, MD, PhD, BSc, Janet Lee, MD, Steven M. Albelda, MD

Blood (2012) 120 (21): SCI-47.

https://doi.org/10.1182/blood.V120.21.SCI-47.SCI-47

Published: 2012

Journal Articles

The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma

Aziz Nazha, Dan T. Vogl, MD, MSCE, Una O'Doherty, MD, PhD, Patricia Mangan, CRNP, Kathleen Cunningham, RN, Selina Luger, MD, David L. Porter, MD, Stephen J. Schuster, Marie Gardler, Mary Sell, Don L. Siegel, MD, PhD, BSc, Edward A Stadtmauer, MD

Blood (2010) 116 (21): 2252.

https://doi.org/10.1182/blood.V116.21.2252.2252

Published: 2010

Journal Articles

Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma.

Aziz Nazha, MD, Rachel Cook, MS, MD, Dan T. Vogl, MD, Patricia A. Mangan, APRN, BC, Kimberly Hummel, Kathleen Cunningham, Selina Luger, MD, David Porter, MD, Stephen J. Schuster, MD, Una O'Doherty, Mary Sell, Don L. Siegel, MD, PhD, BSc, Edward A. Stadtmauer, MD

Blood (2009) 114 (22): 2146.

https://doi.org/10.1182/blood.V114.22.2146.2146

Published: 2009

NARROW

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Outcomes in Aggressive B-Cell Non-Hodgkin Lymphomas with Anti-CD19 CAR T-Cell (CTL019) Products Not Meeting Commercial Release Specifications

Combination Anti-Bcma and Anti-CD19 CAR T Cells As Consolidation of Response to Prior Therapy in Multiple Myeloma

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL)

CD19-Directed CAR T-Cell (CTL019) Product Viability and Clinical Outcomes in Non-Hodgkin Lymphomas and B-Cell Acute Lymphoblastic Leukemia

Prospective Clinical Trial of Anti-CD19 CAR T Cells in Combination with Ibrutinib for the Treatment of Chronic Lymphocytic Leukemia Shows a High Response Rate

Clinical Predictors of T Cell Fitness for CAR T Cell Manufacturing and Efficacy in Multiple Myeloma

Identification of Functional Determinants of Response and Resistance to CD19 Chimeric Antigen Receptor (CAR) T-Cell Therapy of Chronic Lymphocytic Leukemia

Erythrocyte Rigidity Affects Blood Clot Contraction and Formation of Polyhedrocytes

Coupling Therapeutics to Human Erythrocytes Demonstrates Target-Dependent Effects on Red Cell Physiology While Preserving Efficacy

Thrombomodulin Fusion Proteins Coupled to Human Erythrocytes Demonstrate Anti-Thrombotic and Anti-Inflammatory Activity

Inhibition of ADAMTS13 Activity By Human Neutrophil Peptide 1 (HNP-1): Potential Link Between Inflammation, Onset of Thrombotic Thrombocytopenic Purpura, and Other Thrombosis

Autoantibody Epitope Mapping By Hydrogen-Deuterium Exchange Mass Spectrometry at Nearly Single Amino Acid Residue Resolution Reveals Novel Exosites on ADAMTS13 Critical for Substrate Recognition and Mechanism of Autoimmune Thrombotic Thrombocytopenic Purpura

Erythrocyte Advanced Glycation End-Products as Novel Mediators of Endothelial Dysfunction Following Transfusion

The Optimal Timing for Stem Cell Collection After Induction Therapy for Patients with Multiple Myeloma

Plerixafor and G-CSF Versus Cyclophosphamide and G-CSF for Stem Cell Mobilization in Patients with Multiple Myeloma.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only